Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome Boursier

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2024
Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL StudySarra Smati, Matthieu Wargny, Jerome Boursier, et al.
Hepatology International|June 8, 2024
Review of current and new drugs for the treatment of metabolic-associated fatty liver diseaseRobert Gish, Jian-Gao Fan, Zahra Dossaji, et al.
Clinics and Research in Hepatology and Gastroenterology|August 19, 2019
Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patientsThomas Broussier, Adrien Lannes, Floraine Zuberbuhler, et al.
Digestive Diseases and Sciences|May 25, 2021
Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study)Oumarou Nabi, Jerome Boursier, Karine Lacombe, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 18, 2020
Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic reviewJenny Lee, Yasaman Vali, Jerome Boursier, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2023
The NAFLD burden on mortality and morbidities in general population: A community-based longitudinal study (NASH-CO study)Oumarou Nabi, Nathanaël Lapidus, Jerome Boursier, et al.
Nature Reviews. Disease Primers|March 6, 2025
Metabolic dysfunction-associated steatotic liver disease in adultsDaniel Q Huang, Vincent W S Wong, Mary E Rinella, et al.
Hepatology Communications|January 29, 2024
Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitisSven M Francque, Alexander Hodge, Jerome Boursier, et al.
Plos One|June 30, 2015
Correction: Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human DiseaseMariana Verdelho Machado, Gregory Alexander Michelotti, Guanhua Xie, et al.
Hepatology (Baltimore, Md.)|February 23, 2023
Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)Oumarou Nabi, Nathanaël Lapidus, Jerome Boursier, et al.
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2024
Prevalence of Liver Steatosis and Fibrosis in Adults With Primary Hypobetaliproteinemia: Results From the HYPOCHOL StudySarra Smati, Matthieu Wargny, Jerome Boursier, et al.
Hepatology International|June 8, 2024
Review of current and new drugs for the treatment of metabolic-associated fatty liver diseaseRobert Gish, Jian-Gao Fan, Zahra Dossaji, et al.
Clinics and Research in Hepatology and Gastroenterology|August 19, 2019
Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patientsThomas Broussier, Adrien Lannes, Floraine Zuberbuhler, et al.
Digestive Diseases and Sciences|May 25, 2021
Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study)Oumarou Nabi, Jerome Boursier, Karine Lacombe, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 18, 2020
Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic reviewJenny Lee, Yasaman Vali, Jerome Boursier, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2023
The NAFLD burden on mortality and morbidities in general population: A community-based longitudinal study (NASH-CO study)Oumarou Nabi, Nathanaël Lapidus, Jerome Boursier, et al.
Nature Reviews. Disease Primers|March 6, 2025
Metabolic dysfunction-associated steatotic liver disease in adultsDaniel Q Huang, Vincent W S Wong, Mary E Rinella, et al.
Hepatology Communications|January 29, 2024
Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitisSven M Francque, Alexander Hodge, Jerome Boursier, et al.
Plos One|June 30, 2015
Correction: Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human DiseaseMariana Verdelho Machado, Gregory Alexander Michelotti, Guanhua Xie, et al.
Hepatology (Baltimore, Md.)|February 23, 2023
Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)Oumarou Nabi, Nathanaël Lapidus, Jerome Boursier, et al.
Pageof 7